The analysts are definitely expecting Arbutus Biopharma's growth to accelerate, with the forecast 52% annualised growth to the end of 2022 ranking favourably alongside historical growth of 12% per annum over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 12% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that Arbutus Biopharma is expected to grow much faster than its industry.